Oral verapamil inhibits platelet thrombus formation in humans. | Zendy

L. L-Lacoste | Zendy; Jules Y.T. Lam | Zendy; Joseph Hung | Zendy; David D. Waters | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oral verapamil inhibits platelet thrombus formation in humans.

Author(s) -

L. L-Lacoste,

Jules Y.T. Lam,

Joseph Hung,

David D. Waters

Publication year - 1994

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.89.2.630

Subject(s) - verapamil , medicine , antithrombotic , aspirin , thrombus , platelet , thrombin , platelet aggregation inhibitor , cardiology , coronary vasodilator , pharmacology , coronary thrombosis , thrombosis , anesthesia , vasodilation , calcium

Calcium antagonists such as verapamil are potent coronary and systemic vasodilators that are used in the treatment of coronary disease. They have also been shown to inhibit platelet aggregation in vitro, but whether they have beneficial antithrombotic effects in humans is unclear, and whether they can potentiate the antithrombotic effects of aspirin is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research